摘要
在全球化和技术交叉渗透的背景下,创新范式已由线性向开放式创新转变,由此对创新政策环境提出了新的要求。本文基于创新范式的视角,系统梳理了创新范式的改变对不同时期欧盟创新药物政策的影响,在此基础上全面分析了欧盟创新药物的政策环境及其运行机制和特点,并结合我国国情,提出应从整合创新主体资源、发挥政府引导作用以及注重供给、环境和需求政策的合力作用等方面,实现我国医药创新的良性循环。
Under the background of globalization and technological penetration, the innovation paradigm has shifted from linear to open innovation, placing new demands on the innovation policy environment. Based on the perspective of innovation paradigm, this paper systematically reviewed its impact on European Union innovation drug policy of different periods, and analyzed the policy environment, operational mechanism and characteristics. Ultimately, combined with our national conditions, it was suggested that our country should achieve a virtuous circle of medical innovation from the aspects of integrating the resources of innovation main body, playing a role in government guidance and focusing on the combined effect of supply, environment and demand policies.
作者
向星萍
伍琳
陈永法
XIANG Xing-ping;WU Lin;CHEN Yong-fa(School of International Pharmaceutical Business,China Pharmaceutical University,Nanjing JIANGSU 211198,China)
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2019年第1期23-28,共6页
Chinese Journal of New Drugs and Clinical Remedies
基金
国家社会科学基金重大项目(15ZDB167)
国家社会科学基金项目(15BZZ052)
关键词
药物
临床试用
政策
欧盟
开放式创新
drugs,investigational
policy
European Union
open innovation
